# EDGAR Filing Document

**Accession Number:** 0001763950
**File Stem:** 0001104659-25-059524
**Filing Date:** 2025-6
**Character Count:** 46844
**Document Hash:** 741e292e708976e7cb1ae43f496bb9e9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-059524.hdr.sgml**: 20250613

**ACCESSION NUMBER**: 0001104659-25-059524

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250613

**DATE AS OF CHANGE**: 20250613

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lantern Pharma Inc.
- **CENTRAL INDEX KEY:** 0001763950
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 463973463
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91536
- **FILM NUMBER:** 251048142

**BUSINESS ADDRESS:**
- **STREET 1:** 1920 MCKINNEY AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75201
- **BUSINESS PHONE:** 972-277-1136

**MAIL ADDRESS:**
- **STREET 1:** 1920 MCKINNEY AVENUE
- **STREET 2:** 7TH FLOOR
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75201

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lantern Pharma
- **DATE OF NAME CHANGE:** 20190108
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Bios Equity Partners, LP
- **CENTRAL INDEX KEY:** 0001813314

**ORGANIZATION NAME:**
- **EIN:** 822422973
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 1751 RIVER RUN, SUITE 400
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76107
- **BUSINESS PHONE:** 817-381-5370

**MAIL ADDRESS:**
- **STREET 1:** 1751 RIVER RUN, SUITE 400
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76107

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 4)**

**Lantern Pharma Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.0001 per share**

*(Title of Class of Securities)*

**51654W101**

*(CUSIP Number)*

**Bios Equity Partners, LP**<br>1751 River Run, Suite 400<br>Fort Worth TX 76107<br>(817) 984-9197

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**06/12/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS FUND I, LP** | Name of reporting person<br>**BIOS FUND I, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**323335.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**323335.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**323335.00** | Aggregate amount beneficially owned by each reporting person<br>**323335.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.00%** | Percent of class represented by amount in Row (11)<br>**3.00%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of shares of common stock, par value $0.0001 per share ("Shares") directly held by Bios Fund I, LP ("Bios Fund I").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS FUND I QP, LP** | Name of reporting person<br>**BIOS FUND I QP, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**189117.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**189117.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**189117.00** | Aggregate amount beneficially owned by each reporting person<br>**189117.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.75%** | Percent of class represented by amount in Row (11)<br>**1.75%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of Shares directly held by Bios Fund I QP, LP ("Bios Fund I QP").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS FUND II, LP** | Name of reporting person<br>**BIOS FUND II, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**114272.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**114272.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**114272.00** | Aggregate amount beneficially owned by each reporting person<br>**114272.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**1.06%** | Percent of class represented by amount in Row (11)<br>**1.06%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of Shares directly held by Bios Fund II, LP ("Bios Fund II").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS FUND II QP, LP** | Name of reporting person<br>**BIOS FUND II QP, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**373178.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**373178.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**373178.00** | Aggregate amount beneficially owned by each reporting person<br>**373178.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**3.46%** | Percent of class represented by amount in Row (11)<br>**3.46%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of Shares directly held by Bios Fund II QP, LP ("Bios Fund II QP").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS FUND II NT, LP** | Name of reporting person<br>**BIOS FUND II NT, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**49957.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**49957.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**49957.00** | Aggregate amount beneficially owned by each reporting person<br>**49957.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.46%** | Percent of class represented by amount in Row (11)<br>**0.46%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of Shares directly held by Bios Fund II NT, LP ("Bios Fund II NT").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BP DIRECTORS, LP** | Name of reporting person<br>**BP DIRECTORS, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**26093.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**26093.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**26093.00** | Aggregate amount beneficially owned by each reporting person<br>**26093.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.24%** | Percent of class represented by amount in Row (11)<br>**0.24%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of Shares directly held by BP Directors, LP ("BP Directors").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS EQUITY PARTNERS, LP** | Name of reporting person<br>**BIOS EQUITY PARTNERS, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**538545.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**538545.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**538545.00** | Aggregate amount beneficially owned by each reporting person<br>**538545.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.99%** | Percent of class represented by amount in Row (11)<br>**4.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP and (iii) 26,093 Shares directly held by BP Directors. Bios Equity Partners, LP ("Bios Equity I") is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. In its capacity as the general partner of these entities, Bios Equity I may be deemed to have shared voting and/or dispositive power with respect to securities directly held by these entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS EQUITY PARTNERS II, LP** | Name of reporting person<br>**BIOS EQUITY PARTNERS II, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**537407.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**537407.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**537407.00** | Aggregate amount beneficially owned by each reporting person<br>**537407.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**4.98%** | Percent of class represented by amount in Row (11)<br>**4.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 114,272 Shares directly held by Bios Fund II, (ii) 373,178 Shares directly held by Bios Fund II QP and (iii) 49,957 Shares directly held by Bios Fund II NT. Bios Equity Partners II, LP ("Bios Equity II") is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. In its capacity as the general partner of these entities, Bios Equity II may be deemed to have shared voting and/or dispositive power with respect to Shares directly or indirectly held by these entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**CAVU MANAGEMENT, LP** | Name of reporting person<br>**CAVU MANAGEMENT, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075952.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075952.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Cavu Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by Bios Fund I, Bios Fund I QP, BP Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities").

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS CAPITAL MANAGEMENT, LP** | Name of reporting person<br>**BIOS CAPITAL MANAGEMENT, LP** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075952.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075952.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Capital Management, LP ("Bios Management") is a general partner of Bios Equity I and Bios Equity II. In its capacity as a general partner of Bios Equity I and Bios Equity II, Bios Management may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**CAVU ADVISORS, LLC** | Name of reporting person<br>**CAVU ADVISORS, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075952.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075952.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, LLC ("Cavu Advisors") is the general partner of Cavu Management, and therefore may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**BIOS ADVISORS GP, LLC** | Name of reporting person<br>**BIOS ADVISORS GP, LLC** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**TEXAS** | Citizenship or place of organization<br>**TEXAS** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075952.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075952.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**PN** | Type of Reporting Person (See Instructions)<br>**PN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors GP, LLC ("Bios Advisors") is the general partner of Bios Management, and therefore, may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**LESLIE W. KREIS** | Name of reporting person<br>**LESLIE W. KREIS** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075952.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075952.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management is a general partner of Bios Equity I and Bios Equity II. Cavu Advisors, an entity controlled by Mr. Kreis, is the general partner of Cavu Management. As the manager of Cavu Advisors, Mr. Kreis may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

| **CUSIP No.** | **51654W101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**AARON G.L. FLETCHER** | Name of reporting person<br>**AARON G.L. FLETCHER** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**AF** | Source of funds (See Instructions)<br>**AF** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**1075952.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**1075952.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | Aggregate amount beneficially owned by each reporting person<br>**1075952.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**9.98%** | Percent of class represented by amount in Row (11)<br>**9.98%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** Shared voting and dispositive power consists of (i) 323,335 Shares directly held by Bios Fund I, (ii) 189,117 Shares directly held by Bios Fund I QP, (iii) 26,093 Shares directly held by BP Directors (iv) 114,272 Shares directly held by Bios Fund II, (v) 373,178 Shares directly held by Bios Fund II QP and (vi) 49,957 Shares directly held by Bios Fund II NT. Bios Equity I is the general partner of Bios Fund I, Bios Fund I QP and BP Directors. Bios Equity II is the general partner of Bios Fund II, Bios Fund II QP and Bios Fund II NT. Bios Management is a general partner of Bios Equity I and Bios Equity II. Bios Advisors, an entity controlled by Dr. Fletcher, is the general partner of Bios Management. As the manager of Bios Advisors, Dr. Fletcher may be deemed to have shared voting and/or dispositive power with respect to securities directly held by the Bios Equity Entities.

Percentage based on 10,784,725 outstanding Shares as reported in the Form 10-Q filed by the Issuer on May 15, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.0001 per share

**(b) Name of Issuer:**
Lantern Pharma Inc.

**(c) Address of Issuer's Principal Executive Offices:**
1920 MCKINNEY AVENUE, 7TH FLOOR, DALLAS, TX, 75201

This Amendment No. 4 hereby amends and supplements the statement on Schedule 13D originally filed with the Securities and Exchange Commission (the "Commission") on June 15, 2020 (the "Original Schedule 13D"), as amended by the statement on Schedule 13D/A filed with the Commission on March 22, 2022 ("Amendment No. 1"), as further amended by the statement on Schedule 13D/A filed with the Commission on December 1, 2023 ("Amendment No. 2"), as further amended by the statement on Schedule 13D/A filed with the Commission on March 1, 2024 ("Amendment No. 3" and, together with the Original Schedule 13D, Amendment No. 1 and Amendment No. 2, the "Prior Statements"). The securities to which the Schedule 13D relates are the shares of common stock, par value $0.0001 per share (the "Shares"), of Lantern Pharma, Inc., a Delaware corporation (the "Issuer").

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.

**(b)**
The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.

**(c)**
On May 27, 2025, (i) Bios Fund I sold 6,479 Shares, Bios Fund I QP sold 3,790 Shares, (iii) Bios Fund II sold 2,290 Shares, (iv) Bios Fund II QP sold 7,478 Shares and (v) Bios Fund II NT sold 1,000 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.05 on the open market at prices ranging between $2.87 to $3.21, inclusive.

On May 28, 2025, (i) Bios Fund I sold 4,620 Shares, Bios Fund I QP sold 2,702 Shares, (iii) Bios Fund II sold 1,632 Shares, (iv) Bios Fund II QP sold 5,332 Shares and (v) Bios Fund II NT sold 714 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $2.87 on the open market at prices ranging between $2.85 to $2.94, inclusive.

On May 29, 2025, (i) Bios Fund I sold 6,221 Shares, Bios Fund I QP sold 3,639 Shares, (iii) Bios Fund II sold 2,199 Shares, (iv) Bios Fund II QP sold 7,180 Shares and (v) Bios Fund II NT sold 961 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.03 on the open market at prices ranging between $3.00 to $3.13, inclusive.

On June 10, 2025, (i) Bios Fund I sold 5 Shares, Bios Fund I QP sold 3 Shares, (iii) Bios Fund II sold 2 Shares, (iv) Bios Fund II QP sold 5 Shares and (v) Bios Fund II NT sold 1 Share, all such sales in clauses (i)-(v) of this sentence being sold at a price of $3.40 on the open market.

On June 11, 2025, (i) Bios Fund I sold 293 Shares, Bios Fund I QP sold 171 Shares, (iii) Bios Fund II sold 103 Shares, (iv) Bios Fund II QP sold 338 Shares and (v) Bios Fund II NT sold 45 Shares, all such sales in clauses (i)-(v) of this sentence being sold at a price of $3.40 on the open market.

On June 12, 2025, (i) Bios Fund I sold 18,678 Shares, Bios Fund I QP sold 10,925 Shares, (iii) Bios Fund II sold 6,601 Shares, (iv) Bios Fund II QP sold 21,557 Shares and (v) Bios Fund II NT sold 2,886 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.38 on the open market at prices ranging between $3.25 to $3.57, inclusive.

On June 13, 2025, (i) Bios Fund I sold 12,319 Shares, Bios Fund I QP sold 7,206 Shares, (iii) Bios Fund II sold 4,354 Shares, (iv) Bios Fund II QP sold 14,218 Shares and (v) Bios Fund II NT sold 1,903 Shares, all such sales in clauses (i)-(v) of this sentence being sold at an average price of $3.09 on the open market at prices ranging between $3.05 to $3.26, inclusive.

The reporting persons undertake to provide to the Issuer, any security holder of the Isser, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS FUND I, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS FUND I QP, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS FUND II, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS FUND II QP, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS FUND II NT, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BP DIRECTORS, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS EQUITY PARTNERS, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS EQUITY PARTNERS II, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** CAVU MANAGEMENT, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS CAPITAL MANAGEMENT, LP

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** CAVU ADVISORS, LLC

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** BIOS ADVISORS GP, LLC

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** LESLIE W. KREIS

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** AARON G.L. FLETCHER

**Signature:** John Fucci

**Name/Title:** Attorney-in-Fact

**Date:** 06/13/2025